Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer

Molecular Therapy

Volumn 20, Issue 4, 2012, Pages 759-768

  Wennier, Sonia Tusell ^a,b   Liu, Jia ^a   Li, Shoudong ^a   Rahman, Masmudur M ^a   Mona, Mahmoud ^a   McFadden, Grant ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b Bavarian Nordic GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; ONCOLYTIC MYXOMA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS CANCER; TREATMENT RESPONSE; VIRUS REPLICATION;

ANIMALIA; MURINAE; MYXOMA VIRUS;

EID: 84862820881     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.293     Document Type: Article

References (42)

1. Jemal, A, Siegel, R, Xu, J and Ward, E (2010). Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Heinemann, V (2001). Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 60: 8-18. (Pubitemid 32041425)
3. Burris, HA 3rd, Moore, MJ, Andersen, J, Green, MR, Rothenberg, ML, Modiano, MR et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413. (Pubitemid 27251144)
4. Strimpakos, A, Saif, MW and Syrigos, KN (2008). Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 27: 495-522.
5. Nakano, Y, Tanno, S, Koizumi, K, Nishikawa, T, Nakamura, K, Minoguchi, M et al. (2007). Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 96: 457-463. (Pubitemid 46215217)
6. El Maalouf, G, Le Tourneau, C, Batty, GN, Faivre, S and Raymond, E (2009). Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat Rev 35: 167-174.
7. Welch, SA and Moore, MJ (2007). Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag? J Clin Oncol 25: 2159-2161. (Pubitemid 46954636)
8. Mackenzie, RP and McCollum, AD (2009). Novel agents for the treatment of adenocarcinoma of the pancreas. Expert Rev Anticancer Ther 9: 1473-1485.
9. Kasuya, H, Takeda, S, Nomoto, S and Nakao, A (2005). The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther 12: 725-736. (Pubitemid 41208612)
10. Liu, TC, Galanis, E and Kirn, D (2007). Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 4: 101-117. (Pubitemid 46189539)
11. Shen, Y and Nemunaitis, J (2006). Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 13: 975-992. (Pubitemid 44564734)
12. Davis, JJ and Fang, B (2005). Oncolytic virotherapy for cancer treatment: challenges and solutions. J Gene Med 7: 1380-1389. (Pubitemid 41672396)
13. Vähä-Koskela, MJ, Heikkilä, JE and Hinkkanen, AE (2007). Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-216. (Pubitemid 47126688)
14. Ottolino-Perry, K, Diallo, JS, Lichty, BD, Bell, JC and McCart, JA (2010). Intelligent design: combination therapy with oncolytic viruses. Mol Ther 18: 251-263.
15. Alvarez-Breckenridge, C, Kaur, B and Chiocca, EA (2009). Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev 109: 3125-3140.
16. Sypula, J, Wang, F, Ma, Y, Bell, JC and McFadden, G (2004). Myxoma virus tropism in human tumor cells. Gene Ther Mol Biol 8: 103-114.
17. Stanford, MM and McFadden, G (2007). Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther 7: 1415-1425. (Pubitemid 47475657)
18. McFadden, G (2005). Poxvirus tropism. Nat Rev Microbiol 3: 201-213. (Pubitemid 40298220)
19. Jackson, EW, Dorn, CR, Saito, JK and McKercher, DG (1966). Absence of serological evidence of myxoma virus infection in humans exposed during an outbreak of myxomatosis. Nature 211: 313-314.
20. Fenner, F (2000). Adventures with poxviruses of vertebrates. FEMS Microbiol Rev 24: 123-133. (Pubitemid 30136439)
21. Stanford, MM, Werden, SJ and McFadden, G (2007). Myxoma virus in the European rabbit: interactions between the virus and its susceptible host. Vet Res 38: 299-318. (Pubitemid 46562409)
22. Lun, X, Alain, T, Zemp, FJ, Zhou, H, Rahman, MM, Hamilton, MG et al. (2010). Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res 70: 598-608.
23. Lun, XQ, Zhou, H, Alain, T, Sun, B, Wang, L, Barrett, JW et al. (2007). Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 67: 8818-8827. (Pubitemid 47437458)
24. Lun, X, Yang, W, Alain, T, Shi, ZQ, Muzik, H, Barrett, JW et al. (2005). Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 65: 9982-9990. (Pubitemid 41541479)
25. Wu, Y, Lun, X, Zhou, H, Wang, L, Sun, B, Bell, JC et al. (2008). Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res 14: 1218-1227. (Pubitemid 351302571)
26. Stanford, MM, Shaban, M, Barrett, JW, Werden, SJ, Gilbert, PA, Bondy-Denomy, J et al. (2008). Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 16: 52-59.
27. Wang, G, Barrett, JW, Stanford, M, Werden, SJ, Johnston, JB, Gao, X et al. (2006). Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci USA 103: 4640-4645.
28. Werden, SJ, Barrett, JW, Wang, G, Stanford, MM and McFadden, G (2007). M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. J Virol 81: 2340-2348.
29. Werden, SJ and McFadden, G (2008). The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus. Biochim Biophys Acta 1784: 228-237.
30. Bartee, E and McFadden, G (2009). Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferonbeta. Cytokine 47: 199-205.
31. Woo, Y, Kelly, KJ, Stanford, MM, Galanis, C, Chun, YS, Fong, Y et al. (2008). Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Ann Surg Oncol 15: 2329-2335.
32. Arumugam, T, Ramachandran, V, Fournier, KF, Wang, H, Marquis, L, Abbruzzese, JL et al. (2009). Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res 69: 5820-5828.
33. Li, H, Zeng, Z, Fu, X and Zhang, X (2007). Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. Cancer Res 67: 7850-7855. (Pubitemid 47281380)
34. Myers, RM, Greiner, SM, Harvey, ME, Griesmann, G, Kuffel, MJ, Buhrow, SA et al. (2007). Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 82: 700-710. (Pubitemid 350114828)
35. Currier, MA, Gillespie, RA, Sawtell, NM, Mahller, YY, Stroup, G, Collins, MH et al. (2008). Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther 16: 879-885. (Pubitemid 351587097)
36. Watanabe, I, Kasuya, H, Nomura, N, Shikano, T, Shirota, T, Kanazumi, N et al. (2008). Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer. Cancer Chemother Pharmacol 61: 875-882. (Pubitemid 351302042)
37. Angelova, AL, Aprahamian, M, Grekova, SP, Hajri, A, Leuchs, B, Giese, NA et al. (2009). Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res 15: 511-519.
38. Kim, M, Williamson, CT, Prudhomme, J, Bebb, DG, Riabowol, K, Lee, PW et al. (2010). The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status. Oncogene 29: 3990-3996.
39. Stanford, MM, Barrett, JW, Nazarian, SH, Werden, S and McFadden, G (2007). Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol 81: 1251-1260. (Pubitemid 46167846)
40. Liu, J, Wennier, S, Reinhard, M, Roy, E, MacNeill, A and McFadden, G (2009). Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. J Virol 83: 5933-5938.
41. Johnston, JB, Barrett, JW, Chang, W, Chung, CS, Zeng, W, Masters, J et al. (2003). Role of the serine-threonine kinase PAK-1 in myxoma virus replication. J Virol 77: 5877-5888. (Pubitemid 36538980)
42. Smallwood, SE, Rahman, MM, Smith, DW and McFadden, G (2010). Myxoma virus: propagation, purification, quantification, and storage. Curr Protoc Microbiol Chapter 14: Unit 14A.1.